DK1494993T3 - Hidtil ukendte Curcumin-analoger og anvendelser deraf - Google Patents

Hidtil ukendte Curcumin-analoger og anvendelser deraf

Info

Publication number
DK1494993T3
DK1494993T3 DK03718072.6T DK03718072T DK1494993T3 DK 1494993 T3 DK1494993 T3 DK 1494993T3 DK 03718072 T DK03718072 T DK 03718072T DK 1494993 T3 DK1494993 T3 DK 1494993T3
Authority
DK
Denmark
Prior art keywords
androgen
spermatogenesis
limited
androgen receptor
curcumin analogs
Prior art date
Application number
DK03718072.6T
Other languages
Danish (da)
English (en)
Inventor
Kuo-Hsiung Lee
Junko Ishida
Hironori Ohtsu
Hui-Kang Wang
Hideji Itokawa
Chawnshang Chang
Charles C Y Shih
Original Assignee
Univ North Carolina
Univ Rochester Medical Ct
Androscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Univ Rochester Medical Ct, Androscience Corp filed Critical Univ North Carolina
Application granted granted Critical
Publication of DK1494993T3 publication Critical patent/DK1494993T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/17—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/172—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C07C49/248—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
DK03718072.6T 2002-04-17 2003-03-27 Hidtil ukendte Curcumin-analoger og anvendelser deraf DK1494993T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/124,642 US6790979B2 (en) 2002-04-17 2002-04-17 Curcumin analogues and uses thereof
PCT/US2003/009350 WO2003088927A2 (en) 2002-04-17 2003-03-27 Novel curcumin analogues and uses thereof

Publications (1)

Publication Number Publication Date
DK1494993T3 true DK1494993T3 (da) 2010-08-23

Family

ID=29248380

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03718072.6T DK1494993T3 (da) 2002-04-17 2003-03-27 Hidtil ukendte Curcumin-analoger og anvendelser deraf

Country Status (14)

Country Link
US (1) US6790979B2 (enExample)
EP (1) EP1494993B1 (enExample)
JP (2) JP5108198B2 (enExample)
KR (2) KR101025226B1 (enExample)
CN (1) CN1646473B (enExample)
AT (1) ATE466832T1 (enExample)
AU (1) AU2003222087B8 (enExample)
CA (1) CA2482002C (enExample)
DE (1) DE60332445D1 (enExample)
DK (1) DK1494993T3 (enExample)
ES (1) ES2345930T3 (enExample)
MX (1) MXPA04010180A (enExample)
NZ (1) NZ535773A (enExample)
WO (1) WO2003088927A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
AU2002314566A1 (en) * 2002-06-17 2003-12-31 Ho-Jeong Kwon Novel curcumin derivatives
CA2503549C (en) * 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CN100431545C (zh) * 2003-05-22 2008-11-12 潘塔希生物科学股份有限公司 雌激素成分在制备用于治疗及预防肌与骨疼痛中的组合物中的应用
WO2005020908A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Selective inhibitors of stat-3 activation and uses thereof
CA2549518A1 (en) * 2003-12-12 2005-07-14 University Of Rochester Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
JP2007526913A (ja) * 2004-01-28 2007-09-20 アンドロサイエンス コーポレイション ステロイド依存性の遺伝子活性化経路の異なる段階を標的とする阻害剤の組み合わせによる抗アンドロゲン活性の増強およびその使用
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
EP1804806A2 (en) * 2004-09-02 2007-07-11 AndroScience Corporation Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
EP1797072A4 (en) * 2004-09-17 2009-09-09 Exelixis Inc PYRAZOLKINASE MODULATORS AND USE METHOD
FR2880276A1 (fr) * 2005-01-05 2006-07-07 Lefebvre Dominique Caparros Utilisation des anti-androgenes dans le traitement des comportements agressifs ou impulsifs induits par des maladies du systeme nerveux central
JP2009537142A (ja) * 2006-05-19 2009-10-29 ユニバーシティー オブ ロチェスター 前立腺上皮アンドロゲン受容体は、前立腺の成長および腫瘍の侵襲を抑制する
US7507864B2 (en) * 2006-08-01 2009-03-24 Salisbury University Method for the synthesis of curcumin analogues
CA2665916C (en) * 2006-10-12 2015-12-08 The Research Foundation Of The City University Of New York Novel curcumin and tetrahydrocurcumin derivatives
CN101711231B (zh) * 2007-01-08 2014-03-12 安德鲁科技有限公司 具有(取代苯基)-丙烯醛部分的化合物、它们的衍生物、生物活性及其用途
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
CN102432447B (zh) * 2007-01-22 2014-01-08 温州医学院生物与天然药物开发中心有限公司 含环戊酮的姜黄素单羰基结构类似物及其用途
CN101003470B (zh) * 2007-01-22 2011-11-02 温州医学院生物与天然药物开发中心有限公司 姜黄素单羰基结构类似物及其用途
CN102381951B (zh) * 2007-01-22 2013-09-04 温州医学院生物与天然药物开发中心有限公司 含环己酮的姜黄素单羰基结构类似物及其用途
US8383865B2 (en) * 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
WO2008131059A2 (en) * 2007-04-17 2008-10-30 Codman & Shurtleff, Inc. Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease
KR20100051808A (ko) 2007-07-31 2010-05-18 앤드로사이언스 코포레이션 안드로겐 수용체 분해 강화제를 포함한 조성물 및 탈모와 피부질환의 예방 또는 치료 방법
CN101255119B (zh) * 2008-01-07 2014-05-21 沈阳药科大学 四氢姜黄素衍生物及盐类
US20090282496A1 (en) * 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer
JP5481739B2 (ja) * 2008-05-30 2014-04-23 国立大学法人東京工業大学 アルツハイマー病治療薬
CN101434525B (zh) * 2008-06-05 2012-07-04 福建医科大学 4-(4-羟基-3-甲氧基苯甲基)姜黄素及其用于制备抗肿瘤药物的应用
US7985776B2 (en) * 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
WO2010033580A2 (en) * 2008-09-19 2010-03-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Curcumin conjugates for treating and preventing cancers
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US20100286585A1 (en) * 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
CN101805285B (zh) * 2009-02-13 2012-02-22 南华大学 含烟酸姜黄素酯衍生物及其制造方法和用途
EP3206488B1 (en) 2009-05-15 2019-08-21 The Research Foundation for The State University of New York Curcumin analogues as zinc chelators and their uses
CN101570515B (zh) * 2009-06-12 2011-10-19 乐山师范学院 姜黄素取代嘧啶类衍生物及其制备方法与用途
CN102091060A (zh) * 2009-12-10 2011-06-15 温州医学院 治疗或预防糖皮质激素介导的性腺功能减退性功能障碍和/或不育的药物及其应用
WO2011116066A1 (en) 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
CN102126938B (zh) * 2010-12-15 2013-03-27 厦门大学 一种姜黄素类似物及其制备方法和应用
BR112013025881A2 (pt) 2011-04-11 2017-10-17 Pharma Eight Co Ltd composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
WO2013076275A1 (en) * 2011-11-23 2013-05-30 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv.Trinity Of Queen Elizabeth Near Dublin Androgen receptor ligands
CN102649750B (zh) * 2012-04-11 2014-01-22 福建医科大学 姜黄素水杨酰单酯及其合成方法以及其在抗肿瘤、抗炎方面的应用
ES2775173T3 (es) * 2012-06-18 2020-07-24 Allianz Pharmascience Ltd Compuestos con armazón estructural de (1E,6E)-1,7-bis-(3,4-dimetoxifenil)-4,4-disustituido-hepa-1,6-dieno-3,5-di-ona, su actividad biológica y usos de los mismos
WO2014005089A2 (en) 2012-06-29 2014-01-03 The Research Foundation Of State University Of New York Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
US20160008297A1 (en) * 2012-08-23 2016-01-14 B.R.A.I.N. Biotechnology Research And Information Network Ag Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
JP6284158B2 (ja) 2012-10-10 2018-02-28 グリーン・テック株式会社 新規ピラゾール誘導体
CN103159644B (zh) * 2013-04-08 2015-04-15 唐山师范学院 类姜黄素缩芳香胺希夫碱衍生物及其在制备抗菌药物的应用
CN103222970B (zh) * 2013-04-10 2019-03-26 温州医科大学 不对称单羰基姜黄素类似物在制备抗肿瘤药物中的应用
CN103254051B (zh) * 2013-05-28 2015-08-12 常州大学 一种二烷基姜黄素的制备方法
JP6369751B2 (ja) * 2014-09-05 2018-08-08 二村　芳弘 ケラチン産生作用を呈するクルクミン誘導体及びその製造方法
US20160106722A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
CN104557496B (zh) * 2015-01-21 2018-03-16 温州医科大学 单羰基类化合物、组合物及在制备药物中的应用
WO2018005732A1 (en) 2016-06-29 2018-01-04 The General Hospital Corporation Half-curcuminoids as amyloid-beta pet imaging agents
US10300000B2 (en) 2016-09-12 2019-05-28 The Research Foundation For The State University Of New York Inhibition of melanogenesis by chemically modified curcumins
CN106800547B (zh) * 2017-01-03 2019-07-23 中国人民解放军第二军医大学 一种双取代芳基类化合物及其应用
AU2018220664B2 (en) * 2017-02-15 2020-04-02 Unilever Global Ip Limited A personal care composition
AU2018261331C1 (en) 2017-05-01 2022-08-04 Spg Therapeutics, Inc. Tripartite androgen receptor eliminators, methods and uses thereof
CN111315370B (zh) * 2018-07-28 2023-09-29 苏州沪云新药研发股份有限公司 一种具有抗炎症性肠病作用的药物及其制备方法和应用
CA3153879A1 (en) * 2019-10-15 2021-04-22 Muhammed Majeed Curcuminoid composition for therapeutic management of metabolic syndrome
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07165724A (ja) * 1993-12-13 1995-06-27 Nkk Corp ピラゾール誘導体及び血液凝固阻害剤
IL112205A0 (en) * 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5679864A (en) * 1995-11-03 1997-10-21 Gene Print Inc. Process for the synthesis of curcumin-related compounds
WO1999022728A1 (en) * 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
JP2000258904A (ja) * 1999-03-04 2000-09-22 Fujifilm Olin Co Ltd ネガ型化学増幅系感光性組成物
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
AU2300001A (en) 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
CA2393440A1 (en) 1999-12-03 2001-06-07 Emory University Curcumin analogs with anti-tumor and anti-angiogenic properties
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
CN1720030A (zh) * 2002-12-06 2006-01-11 帝斯曼知识产权资产管理有限公司 番茄红素的新用途
WO2004080396A2 (en) * 2003-03-07 2004-09-23 The University Of Texas Md Anderson Cancer Center Liposomal curcumin for treatment of cancer

Also Published As

Publication number Publication date
AU2003222087B8 (en) 2008-09-04
KR101025226B1 (ko) 2011-04-01
NZ535773A (en) 2007-01-26
EP1494993A2 (en) 2005-01-12
CN1646473A (zh) 2005-07-27
CN1646473B (zh) 2010-10-13
DE60332445D1 (de) 2010-06-17
KR20050009989A (ko) 2005-01-26
EP1494993B1 (en) 2010-05-05
JP2010150266A (ja) 2010-07-08
US6790979B2 (en) 2004-09-14
US20030203933A1 (en) 2003-10-30
AU2003222087A1 (en) 2003-11-03
HK1078846A1 (en) 2006-03-24
KR20090132590A (ko) 2009-12-30
JP2005534626A (ja) 2005-11-17
CA2482002A1 (en) 2003-10-30
EP1494993A4 (en) 2005-09-14
WO2003088927A3 (en) 2004-04-01
WO2003088927A2 (en) 2003-10-30
JP5108198B2 (ja) 2012-12-26
KR100984512B1 (ko) 2010-09-30
CA2482002C (en) 2012-07-17
ES2345930T3 (es) 2010-10-06
MXPA04010180A (es) 2005-02-03
ATE466832T1 (de) 2010-05-15
AU2003222087B2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
DK1494993T3 (da) Hidtil ukendte Curcumin-analoger og anvendelser deraf
SG141468A1 (en) Novel curcumin analogues and uses thereof
NO20034122L (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
HRP20150437T1 (xx) Diarilhidantoinski spojevi kao antagonisti androgenog receptora za lijeäśenje raka
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
MXPA03011940A (es) Ligandos del receptor de 5-ht- y sus usos.
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
UA94571C2 (en) 3-arylamino pyridine derivatives
SG151303A1 (en) New compounds for the inhibition of angiogenesis and use thereof
CY1113538T1 (el) Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου
ATE520668T1 (de) Sigmarezeptor-inhibitoren
DE60309667D1 (de) Biphenylderivate und ihre verwendung als antiandrogene
NZ598144A (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
CY1112709T1 (el) Ανταγωνιστες υποδοχεα 5-ητ7
DE60230194D1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7-dimethylbicycloä2.2.1ühept-1-ylmethanesulphonamide-familie
DE60328772D1 (de) Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
JO2550B1 (en) Pyrido [3,2-d] derivatives pyrimidine, its preparation, use therapeutically
NO983724L (no) 17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
IL165323A0 (en) Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
IL164218A0 (en) Use of interleukin-19 to treat ovarian cancer
TW200606148A (en) Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands